Obesity is the most common nutritional disorder of cats and is a risk factor for diabetes. Similar to developments in obese people, obese cats show peripheral tissue insulin resistance and may demonstrate glucose intolerance when challenged with pharmacological amounts of glucose. However, they compensate well for the insulin resistance and do not show elevated glucose concentrations when monitored during their regular daily routine, including postprandial periods. This is possible because obese cats in the fasted and postprandial state are able to maintain hepatic insulin sensitivity and decrease endogenous glucose production, which allows them to maintain normoglycemia. Also dissimilar to what is seen in many obese humans, cats do not develop atherosclerosis and clinical hypertension. The time course for progression to overt diabetes of obese cats is unknown. One might speculate that diabetes develops when the liver finally becomes insulin resistant and/or insulin secretion becomes too low to overcome increased glucose production. In addition, amyloid, demonstrated to be deposited in islet of chronically obese cats, may contribute to a reduction in insulin secretion by reducing functional β-cell mass.
CourcierEAO'HigginsRMellorDJYamPS. Prevalence and risk factors for feline obesity in a first opinion practice in Glasgow, Scotland. J Feline Med Surg.2010;12 (10): 746–53.
2.
ScarlettJMDonoghueS. Associations between body condition and disease in cats. J Am Vet Med Assoc.1998;212 (11): 1725–31.
3.
LaflammeD. Development and validation of a body condition score system for cats: A clinical tool. Feline Pract.1997;25 (5–6): 13–8.
4.
NelsonRWHimselCAFeldmanECBottomsGD. Glucose tolerance and insulin response in normal-weight and obese cats. Am J Vet Res.1990;51 (9): 1357–62.
5.
HawthorneAButterwickR. Predicting the body composition of cats: Development of a zoometric measurement for estimation of percentage body fat in cats. J Vet Intern Med.2000;14 (3): 365.
6.
WilkinsCLongRCJrWaldronMFergusonDCHoenigM. Assessment of the influence of fatty acids on indices of insulin sensitivity and myocellular lipid content by use of magnetic resonance spectroscopy in cats. Am J Vet Res.2004;65 (8): 1090–9.
7.
HoenigMThomasethKWaldronMFergusonDC. Insulin sensitivity, fat distribution, and adipocytokine response to different diets in lean and obese cats before and after weight loss. Am J Physiol Regul Integr Comp Physiol.2007;292 (1): R227–34.
8.
SpeakmanJRBoolesDButterwickR. Validation of dual energy X-ray absorptiometry (DXA) by comparison with chemical analysis of dogs and cats. Int J Obes Relat Metab Disord.2001;25 (3): 439–47.
9.
WagenknechtLELangefeldCDScherzingerALNorrisJMHaffnerSMSaadMFBergmanRN. Insulin sensitivity, insulin secretion, and abdominal fat: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes.2003;52 (10): 2490–6.
10.
RussellKSabinRHoltSBradleyRHarperEJ. Influence of feeding regimen on body condition in the cat. J Small Anim Pract.2000;41 (1): 12–7.
11.
PrahlAGuptillLGlickmanNWTetrickMGlickmanLT. Time trends and risk factors for diabetes mellitus in cats presented to veterinary teaching hospitals. J Feline Med Surg.2007;9 (5): 351–8.
12.
McCannTMSimpsonKEShawDJButtJAGunn-MooreDA. Feline diabetes mellitus in the UK: The prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. J Feline Med Surg.2007;9 (4): 289–99.
13.
ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes.1988;37 (12): 1595–607.
14.
Schrauwen-HinderlingVBHesselinkMKSchrauwenPKooiME. Intramyocellular lipid content in human skeletal muscle. Obesity (Silver Spring).2006;14 (3): 357–67.
15.
HoenigMMcGoldrickJBdeBeerMDemackerPNFergusonDC. Activity and tissue-specific expression of lipases and tumor-necrosis factor alpha in lean and obese cats. Domest Anim Endocrinol.2006;30 (4): 333–44.
16.
PoratO. The effect of tumor necrosis factor alpha on the activity of lipoprotein lipase in adipose tissue. Lymphokine Res.1989;8 (4): 459–69.
17.
KernPASaghizadehMOngJMBoschRJDeemRSimsoloRB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest.1995;95 (5): 2111–9.
18.
HoenigMFergusonDC. Effect of darglitazone on glucose clearance and lipid metabolism in obese cats. Am J Vet Res.2003 Nov; 64 (11): 1409–13.
19.
JonesJGSolomonMASherryADJeffreyFMMalloyCR. 13C NMR measurements of human gluconeogenic fluxes after ingestion of [U-13C]propionate, phenylacetate, and acetaminophen. Am J Physiol.1998;275 (5 Pt 1): E843–52.
20.
JinESBurgessSCMerrittMESherryADMalloyCR. Differing mechanisms of hepatic glucose overproduction in triiodothyronine-treated rats vs. Zucker diabetic fatty rats by NMR analysis of plasma glucose. Am J Physiol Endocrinol Metab.2005;288 (4): E654–62.
21.
BurgessSCLeoneTCWendeARCroceMAChenZSherryADMalloyCRFinckBN. Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha)-defcient mice. J Biol Chem.2006;281 (28): 19000–8.
22.
KleySHoenigMGlushkaJJinESBurgessSCWaldronMJordanETPrestegardJHFergusonDCWuSOlsonDE. The impact of obesity, sex, and diet on hepatic glucose production in cats. Am J Physiol Regul Integr Comp Physiol.2009;296 (4): R936–43.
23.
HoenigMJordanETGlushkaJKleySPatilAWaldronMPrestegardJHFergusonDCWuSOlsonDE. Effect of macro-nutrients, age, and obesity on 6 and 24-hour post-prandial glucose metabolism in cats. Am J Physiol Regul Integr Comp Physiol.2011;301 (6): R1798–807.
24.
KettelhutICFossMCMiglioriniRH. Glucose homeostasis in a carnivorous animal (cat) and in rats fed a high-protein diet. Am J Physiol.1980;239 (5): R437–44.
25.
BallardFJ. Glucose utilization in mammalian liver. Comp Biochem Physiol.1965;14: 437–43.
RothmanDLMagnussonIKatzLDShulmanRGShulmanGI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science.1991;254 (5031): 573–6.
28.
HoenigMHallGFergusonDJordanKHensonMJohnsonKO'BrienT. A feline model of experimentally induced islet amyloidosis. Am J Pathol.2000;157 (6): 2143–50.
29.
HullRLWestermarkGTWestermarkPKahnSE. Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab.2004;89 (8): 3629–43.
30.
MartinLJSiliartBLutzTABiourgeVNguyenPDumonHJ. Postprandial response of plasma insulin, amylin and acylated ghrelin to various test meals in lean and obese cats. Br J Nutr.2010;103 (11): 1610–9.
31.
HensonMSHegstad-DaviesRLWangQHardyRMArmstrongPJJordanKJohnsonKHO'BrienTD. Evaluation of plasma islet amyloid polypeptide and serum glucose and insulin concentrations in nondiabetic cats classified by body condition score and in cats with naturally occurring diabetes mellitus. Am J Vet Res.2011;72 (8): 1052–8.
32.
GalAHoenigMO'BrienTDWalligMSinghK. Histopathology from life-long dietary-induced obese cats and lean controls. Vet Pathol.2010;47 (6S): 150 (abstract).
33.
MaZWestermarkGTJohnsonKHO'BrienTDWestermarkP. Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant, and diabetic cats. Amyloid.1998;5 (4): 255–61.
34.
NelsonRWGriffeySMFeldmanECFordSL. Transient clinical diabetes mellitus in cats: 10 cases (1989–1991). J Vet Intern Med.1999;13 (1): 28–35.
35.
DohanFCLukensFD. Experimental diabetes produced by the administration of glucose. Endocrinology.1948;42 (4): 244–62.
36.
HoenigMThomasethKBrandaoJWaldronMFergusonDC. Assessment and mathematical modeling of glucose turnover and insulin sensitivity in lean and obese cats. Domest Anim Endocrinol.2006;31 (4): 373–89.
37.
HoenigMThomasethKWaldronMFergusonDC. Fatty acid turnover, substrate oxidation, and heat production in lean and obese cats during the euglycemic hyperinsulinemic clamp. Domest Anim Endocrinol.2007;32 (4): 329–38.
38.
PetrusDJJacksonMWKemnitzJWFinegoodDTPancieraD. Assessing insulin sensitivity in the cat: Evaluation of the hyperinsulinemic euglycemic clamp and the minimal model analysis. Res Vet Sci.1998;65 (2): 179–81.
39.
BrennanCLHoenigMFergusonDC. GLUT4 but not GLUT1 expression decreases early in the development of feline obesity. Domest Anim Endocrinol.2004;26 (4): 291–301.
40.
AppletonDJRandJSPriestJSunvoldGD. Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. Am J Vet Res.2001;62 (4): 630–6.
41.
BackusRCCaveNJGanjamVKTurnerJBBiourgeVC. Age and body weight effects on glucose and insulin tolerance in colony cats maintained since weaning on high dietary carbohydrate. J Anim Physiol Anim Nutr (Berl).2010;94 (6): e318–28.
42.
BrehmAThomasethKBernroiderENowotnyPWaldhäuslWPaciniGRodenM. The role of endocrine counterregulation for estimating insulin sensitivity from intravenous glucose tolerance tests. J Clin Endocrinol Metab.2006;91 (6): 2272–8.
43.
BostonRCStefanovskiDMoatePJSumnerAEWatanabeRMBergmanRN. MINMOD millennium: A computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther.2003;5 (6): 1003–15.
44.
FeldhahnJRRandJSMartinG. Insulin sensitivity in normal and diabetic cats. J Feline Med Surg.1999;1 (2): 107–15.
45.
CryerPETseTFClutterWEShahSD. Roles of glucagon and epinephrine in hypoglycemic and nonhypoglycemic glucose counterregulation in humans. Am J Physiol.1984;247 (2 Pt 1): E198–205.
46.
BiourgeVNelsonRWFeldmanECWillitsNHMorrisJGRogersQR. Effect of weight gain and subsequent weight loss on glucose tolerance and insulin response in healthy cats. J Vet Intern Med.1997;11 (2): 86–91.
47.
HoenigMAlexanderSHolsonJFergusonDC. Influence of glucose dosage on interpretation of intravenous glucose tolerance tests in lean and obese cats. J Vet Intern Med.2002;16 (5): 529–32.
48.
O'BrienTDHaydenDWJohnsonKHStevensJB. High dose intravenous glucose tolerance test and serum insulin and glucagon levels in diabetic and non-diabetic cats: Relationships to insular amyloidosis. Vet Pathol.1985;22 (3): 250–61.
49.
NelsonRWHimselCAFeldmanECBottomsGD. Glucose tolerance and insulin response in normal-weight and obese cats. Am J Vet Res.1990;51 (9): 1357–62.
50.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia.1985;28 (7): 412–9.
51.
KatzANambiSSMatherKBaronADFollmannDASullivanGQuonMJ. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab.2000;85 (7): 2402–10.
52.
MuniyappaRLeeSChenHQuonMJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab.2008;294 (1): E15–26.
53.
WallaceTMLevyJCMatthewsDR. Use and abuse of HOMA modeling. Diabetes Care.2004;27 (6): 1487–95.
54.
StefanovskiDAderMRicheyJMKimSPWoolcottOHarrisonLNKolkaCMIonutVDittmannJYaeSCatalanoKJHsuIRMooradianVChiuJDCastroAVZhengDLottatiMKabirMLiuHBergmanRN. Failure of homeostatic model assessment of insulin resistance (HOMA-IR) to detect marked diet-induced insulin resistance in dogs. Abstract 1535. 71st Meeting of the American Diabetes Association, San Diego, California, 2011.
55.
SlingerlandLIRobbenJHvan HaeftenTWKooistraHSRijnberkA. Insulin sensitivity and beta-cell function in healthy cats: Assessment with the use of the hyperglycemic glucose clamp. Horm Metab Res.2007;39 (5): 341–6.
56.
ElahiD. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care.1996;19 (3): 278–86.
57.
VilsbøllTHolstJJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia.2004;47 (3): 357–66.
HoenigMJordanETFergusonDCde VriesF. Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats. Domest Anim Endocrinol.2010;38 (2): 95–102.
60.
ChurchDB. A comparison of intravenous and oral glucose tolerance tests in the dog. Res Vet Sci.1980;29 (3): 353–9.
61.
HoenigMPachNThomasethKde VriesFFergusonDC. Evaluation of long-term glucose homeostasis in lean and obese cats using continuous glucose monitoring. Am J Vet Res. Forthcoming.
62.
SchindlerC. The metabolic syndrome as an endocrine disease: Is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Ther Adv Cardiovasc Dis.2007;1 (1): 7–26.
63.
FreedmanDSOtvosJDJeyarajahEJBarboriakJJAndersonAJWalkerJA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol.1998;18 (7): 1046–53.
64.
GoffDCJrD'AgostinoRBJrHaffnerSMOtvosJD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the insulin resistance atherosclerosis study. Metabolism.2005;54 (2): 264–70.
65.
GriffinBA. Lipoprotein atherogenicity: An overview of current mechanisms. Proc Nutr Soc.1999;58 (1): 163–9.
66.
LiPZhuZLuYGrannemanJG. Metabolic and cellular plasticity in white adipose tissue II: Role of peroxisome proliferator-activated receptor-alpha. Am J Physiol Endocrinol Metab.2005;289 (4): E617–26.
67.
HoenigMCaffallZFergusonDC. Triiodothyronine differentially regulates key metabolic factors in lean and obese cats. Domest Anim Endocrinol.2008;34 (3): 229–37.
68.
HaffnerSMLehtoSRönnemaaTPyöräläKLaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med.1998;339 (4): 229–34.
69.
MahleyRWJiZS. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res.1999;40 (1): 1–16.
70.
LamarcheBTchernofAMoorjaniSCantinBDagenaisGRLupienPJDesprésJ P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the quebec cardiovascular study. Circulation.1997;95 (1): 69–75.
71.
BlakeGJOtvosJDRifaiNRidkerPM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation.2002;106 (15): 1930–7.
72.
JordanEKleySLeNAWaldronMHoenigM. Dyslipidemia in obese cats. Domest Anim Endocrinol.2008;35 (3): 290–9.
73.
ArsenaultBJLemieuxIDesprésJPGagnonPWarehamNJStroesESKasteleinJJKhawKTBoekholdtSM. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-norfolk prospective population study. Atherosclerosis.2009;206 (1): 276–81.
74.
IshiokaKOmachiASasakiNKimuraKSaitoM. Feline adiponectin: Molecular structures and plasma concentrations in obese cats. J Vet Med Sci.2009;71 (2): 189–94.
75.
BackusRCHavelPJGingerichRLRogersQR. Relationship between serum leptin immunoreactivity and body fat mass as estimated by use of a novel gas-phase Fourier transform infrared spectroscopy deuterium dilution method in cats. Am J Vet Res.2000;61 (7): 796–801.
76.
ShibataHSasakiNHonjohTOhishiITakiguchiMIshiokaKAhmedMSolimanMKimuraKSaitoM. Feline leptin: Immunogenic and biological activities of the recombinant protein, and its measurement by ELISA. J Vet Med Sci.2003;65 (11): 1207–11.
77.
AhimaRS. Metabolic actions of adipocyte hormones: Focus on adiponectin. Obesity (Silver Spring).2006;14Suppl 1: 9S–15S.
78.
AhimaRSFlierJS. Leptin. Annu Rev Physiol.2000;62: 413–37.
79.
FergusonDCCaffallZHoenigM. Obesity increases free thyroxine proportionally to nonesterified fatty acid concentrations in adult neutered female cats. J Endocrinol.2007;194 (2): 267–73.
